In accord with keynote lecture regarding the strategy on bio-business 2019, key persons within goverment and industry discuss about implementation of the strategy. Session will be held at exhibition hall and active discussion with floor will be expected.

New medical innovation with gut microbes

The functions of gut microbiota are considered to be important in the creation of new drug-discovery category and extending the future healthy life. They are mainly derived from the gut microbial components themselves and gut microbial metabolites. In this session, we will introduce the latest findings, the effect of gut microorganisms on cardiovascular diseases and the inflammatory suppression effect in intestinal tract by gut microbial lipid metabolites, and discuss future developments of pharmaceutical seeds based on the above-mentioned results.

1. It found that two species, Bacteroides vulgatus and Bacteroides dorei, were significantly decreased in the patients with Coronary Artery Disease. When two species were orally administered to the mice with arteriosclerosis, it significantly suppressed the formation of arteriosclerosis and decreased the activity of LPS (liposaccharides), the inflammatory substances. In addition, the low ratio of two species was found in the feces of the patient with high LPS activity and vice versa. The results indicated the relationship with anti-inflammatory activity. Thus, we develop two species as drug discovery seeds for the suppression of arteriosclerosis2. It becomes well-known that intestinal inflammation relates various diseases. HYA, the gut microbial lipid metabolites, is expected to be a new therapeutic by suppression of inflammatory.

Coordinator

Prof. Jun Ogawa

ProfessorDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto University

New trends of gut microbial function development

Prof. Jun Ogawa

ProfessorDivision of Applied Life Science, Graduate School of Agriculture Kyoto University

ProfessorGraduate school of Commerce and ManagementHitotsubashi University

Opportunity for developing new benchmark index to link Japanese Biotech companies and institutional investors.

Mr. Yoshiyuki Makino

Managing DirectorHead of Japan Office S&P Dow Jones Indices

In Japanese

Mr. Iwaya Shohei

Asset Management One Co., Ltd.

In Japanese

Mr. Hironoshin Nomura

Senior AnalystEquity ResearchMizuho Securities Co.,Ltd.

In Japanese

Mr. Tanaka Tetsuya

Bio-Industry Division DirectorCommerce and Service Industry Policy Group Ministry of Economy, Trade and Industry

In Japanese

Sponsor

Oct.9(Wed.)
16
:
00
~
17
:
00

F204

【S-8】
Twist Bioscience

Pre-Registration required

Twist Bioscience

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and data storage, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at https://twitter.com/TwistBioscience.

Translating Japanese research excellence into new medicines for patients in need: Working together with Boehringer Ingelheim.

Boehringer Ingelheim (BI) was established as a family-owned company in 1885. BI is focusing on developing innovative new treatment approaches providing outstanding value for patients. To achieve this, the company is increasing its commitment to external innovation, and is working with partners from academia and industry wordwide. A growing network of collaborations across the value chain reflects the company's focus on emerging science that could open new avenues leading to the breakthrough medications of the future. Today, we would like to connect with more Japanese innovators who want to work together for better Health with BI.

The Ecosystem for innovative drug creation with Boehringer Ingelheim

Dr. Ioannis Sapountzis

Boehringer Ingelheim

Partnering experiences in Japan and Proposal/Messages to Japanese Innovators

Dr. Henri Doods

Boehringer Ingelheim

Lessons from Boehringer Academy/Innovation Prize

Dr. Yusaku Katada

CEORestore Vision Co., Ltd.

In Japanese

Sponsor

Oct.10(Thu.)
10
:
00
~
11
:
00

F203

【S-11】
Keio University Tonomachi Town - Campus

Pre-Registration required

Bio-venture Ecosystem in the age of Open Innovation2.0

Coordinator

AccuRna Inc.

Bio-venture Ecosystem in the age of Open Innovation2.0

Mr. Tomohiro Anzai

Fast Track Initiative, Inc.

In Japanese

Nanomedicine innovation accelerate with a venture：From diagnosis to drug discovery.

Mr. Takanori Ichiki

iXstream, Inc.

In Japanese

Utilization of AI and cloud in Bio and Drug discovery informatics

Mr. Yutaka Akiyama

Ahead Biocomputing, Co. Ltd.

In Japanese

Sponsor

Oct.10(Thu.)
10
:
00
~
11
:
00

F204

【S-12】
Japan Agency for Medical Research and Development

Pre-Registration required

Development of Advanced Medical Care by Glycotechnology

Coordinator

Prof. Michiie Sakamoto

professordepartment of pathologyKeio University School of Medicine

From sugar to therapy

Prof. Tatsuro Irimura

professorDivision of Glycobiologics, Intractable Disease Research CenterJuntendo University Graduate School of Medicine

Chief Senior ResearcherGlycoscience and Glycotechnology Research Group, Biotechnology Research Institute for Drug Discovery Department of Life Science and Biotechnology National Institute of Advanced Industrial Science and Technology

In Japanese

Development of molecular-targeted antibodies with glycopeptides by chemoenzymatic synthesis

Dr. Yasunori Chiba

Chief Senior ResearcherGlycoscience and Glycotechnology Research Group, Biotechnology Research Institute for Drug Discovery Department of Life Science and BiotechnologyNational Institute of Advanced Industrial Science and Technology

In Japanese

Sponsor

Oct.10(Thu.)
10
:
00
~
11
:
30

F201

【S-9】
Japan Pharmaceutical Manufacturers Association

Pre-Registration requiredSimultaneous interpretation

The growing importance of PPP and precompetitive research collaboration in drug discovery

In the pharmaceutical industry open innovation focusing on competitive research areas is the mainstream. However, PPP and precompetitive research collaboration where multiple pharmaceutical companies team up together to address mutual challenges in drug discovery have become more important than before. One of the reasons behind this trend is that the start point of drug discovery has changed from a hypothetical drug target to a disease-relevant drug target found by better understanding of disease mechanisms. PPP and precompetitive research collaboration are effective and practical mechanisms by which researchers can advance their research using valuable research materials including patient sample and their medical information. There is no doubt that they will be even more important in the near future when precision medicine and personalized medicine will be widely accepted by the society.

Cancer Genome Medicine

On June , this year, cancer genome medicine started in operation in Japan using cancer gene panel such as NCC Oncopanel and FoundationOne. Our national health insurance system reimburse genomic medicine including cancer gene panel and related medical practice only for 11 core hospitals and associated more than 100 hospitals, covering 1% of new cancer patients in Japan. We will clarify the current status and obstacles of japanese cancer genome medicine.

Coordinator

Mr. Mitsuru Miyata

CEOMiyata Institute of Technologies

Cancer Gene Profiling test promotes Cancer Precision Medicine

Dr. hiroshi nishihara

ProfessorGenomics Unit, Keio Cancer Center Keio University School of Medicine

In Japanese

Dr. Nobuya Ishii

Luncheon

Oct.10(Thu.)
12
:
00
~
13
:
00

F201

【L-3】
TAKARA BIO INC.

Pre-Registration required

Development of novel engineered T cell therapies

Prof. Hiroshi Shiku

Professor Mie University Graduate School of Medicine

In Japanese

Sponsor

Oct.10(Thu.)
13
:
30
~
14
:
30

F204

【S-25】
Eli Lilly and Company

Pre-Registration required

Lilly's external innovation ecosystem

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. Eli Lilly and Company is committed to leveraging the world's science and building partnerships to deliver innovative medicines for the benefit of patients. At Lilly, we recognize the important role that your work plays in helping us generate innovation and achieving our common goal: improving the lives of individual patients around the world. In collaboration with our partners, we look for opportunities to help bring important medicines to the patients who need them. https://www.lilly.com/partners. In this seminar, Lilly introduces our current External Innovation Ecosystem, esp. for emerging technology and innovation.

Lilly's external innovation ecosystem

Dr. Gurkeerat Singh

Vice PresidentEmerging Technology and Innovation, Japan and AsiaEli Lilly and Company

Sponsor

Oct.10(Thu.)
13
:
30
~
16
:
30

F202

【S-15】
Japan Agency for Medical Research and Development

Pre-Registration required

The Second Success Story (Drug Discovery/Medical Technology) of Medical Research and Development Programs Focused on Technology Transfer: Acceleration Transformative Research for Medical Innovation (ACT-M/MS)

Applying GMPs to the Biopharmaceutical Manufacturing Supply Chain - An industry collaborative approach to defining best biopharmaceutical practices which are necessary to ensure the safety of the supply chain

Successful, fast movement from Discovery to Clinical Development is more important than ever in capturing value. Ablexis' AlivaMab(TM) Mouse technology brings quality, speed and value in generating development-ready antibodies that meet your target product profile, making it the best in class platform for antibody drug discovery and development. AlivaMab Mouse avoids the false economies of the other available platforms - transgenic, in vitro and humanization.

For outsourcing therapeutic antibody discovery, AlivaMab Discovery Services ("ADS") provides exceptional capabilities in antibody drug discovery. The scientists at ADS have decades of experience in antibody drug discovery, assay development and recombinant antibodies. The team will be your collaborative partners, and will deliver superior quality, speed and value for your project. Today's presentation will review classes of antibody drug discovery platforms, then present the AlivaMab Mouse and finish with case studies in antibody drug discovery at AlivaMab Discovery Services.

Life Science Research and Clinical Trials Environment in Australia

Australia has a vibrant life science ecosystem of medical technology, biotechnology and pharmaceutical companies and research organisation. There are around 140 life science companies listed on the Australian Stock Exchange (ASX). Over 500 medtech companies have products listed on the Australian Register of Therapeutic Goods and around 50 multinational pharmaceutical companies and 400 locally-owned medical biotechnology companies operate in Australia. Australia also has a thriving research industry with particular strengths in immuno-oncology, tropical and infectious diseases and drug development through artificial intelligence. Between 2001 and 2010, Australia ranked sixth in the world in terms of overall output of health and medical publications. In 2016, Scientific American Worldview ranked Australia fifth for innovation. Australia's Government is committed to supporting commercial activity and research. The Government invests around $3 billion each year on supporting medical research projects and enhancing Australia's research infrastructure. In addition, the Government ensures streamlined regulatory processes and attractive tax reforms. These factors have helped make Australia an internationally renowned destination for clinical trials, with 1,000 new trials commenced in Australia annually. In this seminar, we introduce the Australian delegates participating at BioJapan 2019, and outline the life science industry sector and clinical trials environment in Australia.

Coordinator

Mr. David Lawson

Senior Trade CommissionerAustralian Trade and Investment Commission

TBC

Clinical Trials Environment in Australia

Dr. Dan Grant

MTP Connect

Luncheon

Oct.11(Fri.)
12
:
00
~
13
:
30

F205-206

【L-8】
Life Innovation Area Conference

Pre-Registration required

Coordinator

Mr. Mitsuru Miyata

CEOMiyata Institute of Technologies

Dr. Kazuhiro Sakurada

Deputy Program DirectorMedical Sciences Innovation Hub ProgramRIKEN

In Japanese

Prof. Hiroaki Miyata

ProfessorSchool of Medicine Keio University

In Japanese

Prof. Takeharu Yamanaka

Professor (Director, Center for Data Science)Department of BiostatisticsYokohama City University

Nucleic acid drugs are expected as a new modality of next-generation medicines, and many of them are close to commercialization. In addition to antisense nucleic acids, development of siRNAs are now in progress. In this session, we will review the recent progress of nucleic acid drugs. In particular, we will focus on stabilization, DDS, and manufacturing technologies.

Coordinator

Prof. Takeshi Wada

ProfessorFaculty of Pharmaceutical Sciences Tokyo University of Science

Control of backbone stereochemistry provides a new dimension for the optimization of oligonucleotide drug candidates

Engineered T-Cell Therapy -Bench to Bedside-

The first two CAR-T cell therapies were approved in 2017 in US, and now on the market from the following year. Also in Japan, one of the two therapies was approved and its price has been set earlier this year, to be a commercially available treatment. Under the positive circumstances worldwide, development of novel CAR-T cell therapies, as well as TCR-T cell therapies utilizing the similar technology, are being enhanced all the more. In this seminar, we will focus on some examples of such engineered T-cell therapies; 1) allogenic CAR-T which utilize T cells from donors, 2) a case from China (now becoming a major hot spot of CAR-T development), which succeeded in out-license to a global pharma, and 3) clinical development of TCR-T cell therapy in Japan, to share and discuss expectations on commercialization in the near future.

Coordinator

Mr. Masanobu Kimura

Director, President of Gene Therapy Business UnitTakara Bio Inc.

Prof. Waseem Qasim

Cell and Gene TherapyUniversity College London

Competition and Breakthrough in the Space of BCMA Targeted Immunotherapy for Myeloma

Canada is one of the leaders in regenerative medicine innovation. Since the team of Drs. James Till and Ernest McCulloch discovered the stem cell in 1961, Canada has been a hotbed of ground-breaking innovations in regenerative medicine. One such example is the work of Dr. John E. Dick of Toronto University, who received the prestigious Keio Medical Science Prize for his research on cancer stem cells in 2017. Canada's support of a wide range of research and development and commercialization of research in regenerative medicine through investment at the federal and provincial levels combined with various tax incentives and the availability of highly educated talent, makes Canada an attractive destination for your business and investment. This seminar will provide an overview of an unique national funding program, NRC Health Challenge Program, to support high risk, high reward R&D of disruptive technologies in cell therapy and gene therapy. The seminar will feature the Program Director of the Health Challenge Program.We look forward to seeing you!

Program Directorthe Health Challenge ProgramNational Research Council Canada

Sponsor

Oct.9(Wed.)
13
:
00
~
14
:
00

F204

【S-3】
Hitachi, Ltd. / Hitachi Group

Pre-Registration required

Constructing ecosystem for industrial utilization of iPS cells

iPS cells are expected to be powerful tools for drug discovery as well as for regenerative medicine. In Europe and the US, iPS cell banks are being developed for drug discovery, and their use in drug discovery is becoming active. On the other hand, although Japan is ahead of regenerative medicine, it is urgently important for pharmaceutical companies to set up an "Ecosystem for industrial utilization of iPS cells" that accelerates drug discovery. Towards realization, investigation and construction of frameworks that can be provided by disease-specific iPS cells and iPS cells from healthy persons, construction of a system capable of stably supplying high-quality cells, analysis of the current state over the world, and cooperation systems with other cell banks are required. Therefore, members of industry, government, and academia are discussing issues and solutions at COCN (Council on Competitiveness-Nippon). This time, we invited lecturers from academia and industry to be active in the front line. They are going to give lectures on understanding of the current situation and expectations for the future toward constructing an industrial use ecosystem of iPS cells for drug discovery.

Regenerative MedicineToward Development and Commercialization

In 2019, various companies plan to launch regenerative medicine products and existing commercial products of regenerative medicine also conducts life cycle management. Industries are interested in commercial products' activities, such as development, challenges and activities to solve during review period, strategy and current situation at port marketing, and so on. This symposium invites speakers from companies, which has regenerative medicine products approved in 2019 and are facing actual industrialization of regenerative medicine. Then this symposium expects that the audience can feel positive future for regenerative medicine.

Cell Therapy Manufacturing: Challenges and Solutions

While recent progress in regenerative medicine space, manufacturing of cell therapy products has many issues that need to be sorted out.Cooperation among all stakeholders is vital for future progress. In this session, we will organize a panel discussion by 4 leading experts in this space from different sectors that include product development, contract manufacturing, cell source supply and regulatory issue. They will show their current efforts and discuss future perspectives.

Coordinator

Mr. Kunihiko Suzuki

Vice Chairman Forum for Innovative Regenerative Medicine

iPS cell stock project for regenerative medicine

Prof. Naoko Takasu

Professor and Deputy Director, Head of the Medical Applications Promoting OfficeMedical Applications Promothing Office／Facility for iPS Cell TherapyCenter for iPS Cell Research and Application,Kyoto University

Update in iPS Cell Research

Prof. Shinya Yamanaka, a developer and Nobel Prize winner, talks about the progress of research and development of iPS cells, an innovative innovation originated in Japan. Discuss how to bring the fruits of iPS cells research to patients to realize their happiness.

Issues in the rapid industrialization of regenerative medicine

The Forum for Innovative Regenerative Medicine (FIRM) will publish its mid-term report in 2019, and the priority issues in its report are exactly the issues/challenges facing the regenerative medicine industry. In this session, we share the industry's efforts and also introduce their activities for promoting the industrialization and perspectives. The session presents lectures, followed by panel discussion with stakeholders to further clarify the guidepost for establishing and promoting the regenerative medicine industry.

Healthcare Industrial Strategy with Insurance Companies

Japanese Insurance companies have entered the healthcare business since last year. New types of life insurance have been born that aim to improve the health of subscriber ssuch as accompanying insurance. Japanese citizens pay almost the same life insurance premiums as medical expenses. Based on the progress of life science and mobile health, I would like to discuss healthcare business strategies that insurance companies should aim for.

AIST has been playing a leading role in area of research and development of bioproduction in Japan, developing technologies for tightly-sealed plant factory and production of biological medicine, and promoting research in bioinformatics using genome data. Bioproduction system that utilizes biological function for material production, remains designated as one of the nine pillars in "Bio-strategy 2019", developed for the first time in ten years. As AIST is expected to function as a bioeconomy hub, we endeavor to strengthen our position by further developing relevant technologies. In this session, we would like to introduce the present state as well as the prospects of spreading the bioproduction that utilizes a broad range of biomass from microorganisms, animals, as well as plants.

Coordinator

Dr. Koyomi Miyazaki

DirectorDepartment of Life Science and BiotechnologyNational Institute of Advanced Industrial Science and Technology (AIST)

Innovation in Healthcare by Digital Technologies : Diagnosis and Therapy

Digital technology in healthcare is changing the platforms of disease diagnosis, prevention and therapy. In the diagnosis of neuropsychiatric disorders including dementia such as Alzheimer's disease, imaging such as MRI and artificial intelligence (AI) is expected for clinical trials and early diagnosis. In addition, digital therapeutics (DTx), which utilizes digital technology for therapeutic intervention, has also been tried in areas of hypertension, diabetes mellitus, and psychoneurological diseases. DTx using smartphone applications and IoT devices can promote behavior changes in patients and open the way to prevention. However, the establishment of an ecosystem will be a challenge to involve a wide range of stakeholders, including the pharmaceutical industry, regulatory authorities, healthcare professionals, and patients, as well as companies participating in digital technology innovation. In this seminar, the utilization of digital technology in healthcare and the scalability in diagnosis and therapy will be presented.

Emerging Digital Startups in Medical Area

In the medical area, digital startups are emerging and got attentions. In this session, the trend and challenge of startups in medical and healthcare area, and support and incubation of startups are addressed with the leaders in this industry. Featured startups are introduced, and how the data analysis and AI are applied for medical area, and concrete examples and future development are discussed.

Transformation of business models in a circular economy

The concept of the circular economy is reflected not only in environmental policies that address resource depletion and environmental load reduction, but also in growth strategies for creating new businesses, especially in Europe. The introduction of renewable energy for a decarbonized society is a global request after the Paris Agreement, and is linked to the circular economy. In this seminar, we will deepen discussions on the transformation of business models in relation to Japan's environmental policy.

Coordinator

Prof. Daisuke Shibata

Specially Appointed Professor Research Institute for Sustainable Humanosphere, Kyoto University

(tentative) The concept of “Circulating and Ecological Economy (CEE)” and relationship with the bio industry

Mr. Tokutaro Nakai

Director-General for Environmental Policy Ministry of the Environment,Government of Japan

In Japanese

Effects of circular economy on manufacturing business

Prof. Yasushi Umeda

Professor Research into Artifacts, Center for Engineering, School of Engineeringthe University of Tokyo

Japan Bioindustry Association (JBA) celebrated the 30th anniversary of its foundation in 2017. Concomitantly with this anniversary, JBA evolved previous awards to newly established "Japan Bioindustry Award" and "Bioindustry Research Award". The Japan Bioindustry Award is given to an incomparable work which has contributed significantly to bioindustry's development or envisaging significant industry development in near future.The Bioindustry Research Award is given to young researchers engaged in outstanding research activities appreciating practical application potentials.This is the third time to celebrate, that is getting more and more exciting. The award ceremony of these two Awards is going to be held on this occasion and the award lecture by the winners of the Japan Bioindustry Award will be followed. The poster session by the winners of the Bioindustry Research Award will be held after the award lecture.

Biodegradable plastic with marine degradability: research on microbial production system and development of large-scale production

Biocluster Summit 2019 - Bio-Ecosystem in each country and future collaboration -

We will focus on the formation of Bio-Ecosystems, which is an issue in "Biostrategy 2019", introduce and confirm trends in each country, explore the possibility of future collaborations, and at the same time lead to future biostrategy action plans in Japan.

RBC YOKOHAMA Program Pitching Event （Yokohama Day）The pitches will be given by the US and European companies (in the field of Regenerative Medicine, Pharmaceuticals, etc.) aiming to expand into the Japanese market and Japanese companies that have graduated from the acceleration program of the entrepreneur support group CONNECT in San Diego, USA. We’d like you to take advantage of this opportunity and find your new business partners.

The pitches will be given by the leading companies in US and Europe (in the field of Regenerative Medicine, Pharmaceuticals, etc.) aiming to develop and expand into the Japanese market.They will come to Japan based on the invitation program for foreign-affiliated companies "Regional Business Conference" conducted by the City of Yokohama with the support of JETRO and the Ministry of Economy, Trade and Industry.And the pitches will be given by Japanese companies that have graduated from the acceleration program of the entrepreneur support group CONNECT in San Diego, USA. We will have a time for networking after this pitching event, so we'd like you to take advantage of this opportunity and find your new business partners.

TBC

Sponsor

Oct.11(Fri.)
10
:
00
~
11
:
00

F203

【S-17】
Intellectual Property Strategy Network, Inc

Pre-Registration required

Success of bio-venture and its factors

Many bio-ventures have been established and gone out, however there exist a quite few big-successful bio-ventures over the world. The definition of successful ventures may be M&A, or to become large pharmaceutical companies as EXIT, but the success rate is roughly estimated about 0.5 to 1.0% depending on US-BIO data. Compared with the recent success rate of 5.0% of each project at major pharmaceutical companies in Japan, USA and Europe, the efficiency is considerably low.Therefore, in order to increase the success rate of the bio-ventures as much as possible, learning success cases and using failure cases as lessons, well-known experts from INCJ, Daiichi-Sankyo and FCR Partners identify the main issues and analyze success / failure factors from various angles, then we would like to find out some common terms and special terms out of them for the audience. We hope that this lecture will contribute to the development of bio-ventures by providing some hints that can increase the success rate of bio-ventures in Japan.